The Human Milk Oligosaccharide 3’Sialyllactose Promotes Inflammation Resolution and Reduces Atherosclerosis Development in Mice

Macrophages contribute to the induction and resolution of inflammation and play a central role in the chronic low-grade inflammation in cardiovascular diseases caused by atherosclerosis. Human milk oligosaccharides (HMOs) are complex unconjugated glycans unique to human milk that benefit infant health and act as innate immune modulators. Here, we identify the HMO 3’sialyllactose (3’SL) as a natural inhibitor of TLR4-induced low-grade inflammation in macrophages and endothelium. Transcriptome analysis in macrophages revealed that 3’SL attenuates a selected set of inflammatory gene expression and promotes activity of LXR and SREBP. These acute anti-inflammatory effects of 3’SL were associated with reduced histone H3K27 acetylation at a subset of LPS-inducible enhancers distinguished by preferential enrichment for CTCF, IRF2, BCL6, and other transcription factor recognition motifs. In a murine atherosclerosis model, both subcutaneous and oral administration of 3’SL significantly reduced atherosclerosis development and the associated inflammation. This study provides evidence that 3’SL attenuates inflammation by a transcriptional mechanism to reduce atherosclerosis development in the context of cardiovascular disease.

[1]  Seong-il Eyun,et al.  3′-Sialyllactose prebiotics prevents skin inflammation via regulatory T cell differentiation in atopic dermatitis mouse models , 2020, Scientific Reports.

[2]  M. Nieuwdorp,et al.  Microbiome and Cardiovascular Disease. , 2020, Handbook of experimental pharmacology.

[3]  A. Raman,et al.  Understanding the mother-breastmilk-infant “triad” , 2020, Science.

[4]  Mingyao Liu,et al.  Bcl6 modulates innate immunity by controlling macrophage activity and plays critical role in experimental autoimmune encephalomyelitis , 2020, European journal of immunology.

[5]  M. D. de Winther,et al.  Type-I interferons in atherosclerosis , 2019, The Journal of experimental medicine.

[6]  Shang-Yi Chiu,et al.  A reporter mouse for non-invasive detection of toll-like receptor ligands induced acute phase responses , 2019, Scientific Reports.

[7]  T. Osborne,et al.  Inflammation Triggers Liver X Receptor-Dependent Lipogenesis , 2019, Molecular and Cellular Biology.

[8]  M. Mikš,et al.  Toxicological safety assessment of the human‐identical milk oligosaccharide 3′‐sialyllactose sodium salt , 2019, Journal of applied toxicology : JAT.

[9]  M. Giera,et al.  Inhibition of Δ24-dehydrocholesterol reductase activates pro-resolving lipid mediator biosynthesis and inflammation resolution , 2019, Proceedings of the National Academy of Sciences.

[10]  H. Läubli,et al.  Sialic acid–binding immunoglobulin-like lectins (Siglecs) detect self-associated molecular patterns to regulate immune responses , 2019, Cellular and Molecular Life Sciences.

[11]  Longhou Fang,et al.  Regulation of lipid rafts, angiogenesis and inflammation by AIBP , 2019, Current opinion in lipidology.

[12]  Christian M. Metallo,et al.  ApoC-III ASO promotes tissue LPL activity in the absence of apoE-mediated TRL clearance[S] , 2019, Journal of Lipid Research.

[13]  Olga Tanaseichuk,et al.  Metascape provides a biologist-oriented resource for the analysis of systems-level datasets , 2019, Nature Communications.

[14]  L. Bode,et al.  Evidence of human milk oligosaccharides in maternal circulation already during pregnancy: a pilot study. , 2019, American journal of physiology. Endocrinology and metabolism.

[15]  S. Donovan,et al.  Safety evaluation of 3′‐siallylactose sodium salt supplementation on growth and clinical parameters in neonatal piglets , 2019, Regulatory toxicology and pharmacology : RTP.

[16]  K. Moore,et al.  Targeting inflammation in CVD: advances and challenges , 2018, Nature Reviews Cardiology.

[17]  Seon-Yong Jeong,et al.  3′‐Sialyllactose as an inhibitor of p65 phosphorylation ameliorates the progression of experimental rheumatoid arthritis , 2018, British journal of pharmacology.

[18]  P. Libby,et al.  Modulation of the interleukin-6 signalling pathway and incidence rates of atherosclerotic events and all-cause mortality: analyses from the Canakinumab Anti-Inflammatory Thrombosis Outcomes Study (CANTOS) , 2018, European heart journal.

[19]  L. Bode,et al.  Infants Are Exposed to Human Milk Oligosaccharides Already in utero , 2018, Front. Pediatr..

[20]  Max W. Chang,et al.  Transcription Elongation Can Affect Genome 3D Structure , 2018, Cell.

[21]  L. Bode,et al.  Immunological Effects of Human Milk Oligosaccharides , 2018, Front. Pediatr..

[22]  Albert W. Lee,et al.  Toxicological evaluation of 3′‐sialyllactose sodium salt , 2018, Regulatory toxicology and pharmacology : RTP.

[23]  R. V. van Neerven,et al.  Induction of human tolerogenic dendritic cells by 3′-sialyllactose via TLR4 is explained by LPS contamination , 2017, Glycobiology.

[24]  P. Libby,et al.  Relationship of C-reactive protein reduction to cardiovascular event reduction following treatment with canakinumab: a secondary analysis from the CANTOS randomised controlled trial , 2017, The Lancet.

[25]  Wook Kim,et al.  3′‐Sialyllactose protects against osteoarthritic development by facilitating cartilage homeostasis , 2017, Journal of cellular and molecular medicine.

[26]  James R. Springstead,et al.  By Capturing Inflammatory Lipids Released from Dying Cells, the Receptor CD14 Induces Inflammasome‐Dependent Phagocyte Hyperactivation , 2017, Immunity.

[27]  A. Saghatelian,et al.  SREBP1 Contributes to Resolution of Pro-inflammatory TLR4 Signaling by Reprogramming Fatty Acid Metabolism. , 2017, Cell metabolism.

[28]  G. Getz,et al.  Serum amyloid A and atherosclerosis , 2016, Current opinion in lipidology.

[29]  L. Bode,et al.  Overcoming the limited availability of human milk oligosaccharides: challenges and opportunities for research and application. , 2016, Nutrition reviews.

[30]  Richard G. Lee,et al.  ApoC-III inhibits clearance of triglyceride-rich lipoproteins through LDL family receptors. , 2016, The Journal of clinical investigation.

[31]  C. Glass,et al.  Tissue damage drives co-localization of NF-κB, Smad3, and Nrf2 to direct Rev-erb sensitive wound repair in mouse macrophages , 2016, eLife.

[32]  Jennifer A. Williams,et al.  Infants Fed a Lower Calorie Formula With 2′FL Show Growth and 2′FL Uptake Like Breast-Fed Infants , 2015, Journal of pediatric gastroenterology and nutrition.

[33]  W. Watford,et al.  A Neoglycoconjugate Containing the Human Milk Sugar LNFPIII Drives Anti-Inflammatory Activation of Antigen Presenting Cells in a CD14 Dependent Pathway , 2015, PloS one.

[34]  Hong Yang,et al.  A Subregion of Reelin Suppresses Lipoprotein-Induced Cholesterol Accumulation in Macrophages , 2015, PloS one.

[35]  K. Ley,et al.  Macrophages at the Fork in the Road to Health or Disease , 2015, Front. Immunol..

[36]  E. Latz,et al.  Danger signaling in atherosclerosis. , 2015, Circulation research.

[37]  W. Huber,et al.  Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2 , 2014, Genome Biology.

[38]  C. Glass,et al.  Reducing macrophage proteoglycan sulfation increases atherosclerosis and obesity through enhanced type I interferon signaling. , 2014, Cell metabolism.

[39]  P. Libby,et al.  Moderate Hypoxia Potentiates Interleukin-1&bgr; Production in Activated Human Macrophages , 2014, Circulation research.

[40]  J. Paulson,et al.  Siglec-mediated regulation of immune cell function in disease , 2014, Nature Reviews Immunology.

[41]  L. R. Ruhaak,et al.  Detection of milk oligosaccharides in plasma of infants , 2014, Analytical and Bioanalytical Chemistry.

[42]  A. Kennedy,et al.  Direct Evidence for the Presence of Human Milk Oligosaccharides in the Circulation of Breastfed Infants , 2014, PloS one.

[43]  Peter Tontonoz,et al.  Liver X receptors in lipid metabolism: opportunities for drug discovery , 2014, Nature Reviews Drug Discovery.

[44]  Karen L. Bunting,et al.  New effector functions and regulatory mechanisms of BCL6 in normal and malignant lymphocytes. , 2013, Current opinion in immunology.

[45]  G. Sprenger,et al.  Construction of Escherichia coli strains with chromosomally integrated expression cassettes for the synthesis of 2′-fucosyllactose , 2013, Microbial Cell Factories.

[46]  Thomas R. Gingeras,et al.  STAR: ultrafast universal RNA-seq aligner , 2013, Bioinform..

[47]  A. Zernecke,et al.  Improving the treatment of atherosclerosis by linking anti-inflammatory and lipid modulating strategies , 2012, Heart.

[48]  Lars Bode,et al.  Human milk oligosaccharides: every baby needs a sugar mama. , 2012, Glycobiology.

[49]  Michael J. Miller,et al.  Whole cell biosynthesis of a functional oligosaccharide, 2′-fucosyllactose, using engineered Escherichia coli , 2012, Microbial Cell Factories.

[50]  Steven L Salzberg,et al.  Fast gapped-read alignment with Bowtie 2 , 2012, Nature Methods.

[51]  G. Owens,et al.  Genetic inactivation of IL-1 signaling enhances atherosclerotic plaque instability and reduces outward vessel remodeling in advanced atherosclerosis in mice. , 2012, The Journal of clinical investigation.

[52]  Hong Yang,et al.  Up-regulation of ATP Binding Cassette Transporter A1 Expression by Very Low Density Lipoprotein Receptor and Apolipoprotein E Receptor 2* , 2011, The Journal of Biological Chemistry.

[53]  C. Kunz,et al.  Urinary excretion of in vivo 13C-labelled milk oligosaccharides in breastfed infants , 2011, British Journal of Nutrition.

[54]  Peter J. Bickel,et al.  Measuring reproducibility of high-throughput experiments , 2011, 1110.4705.

[55]  J. Schrezenmeir,et al.  Prebiotic oligosaccharides reduce proinflammatory cytokines in intestinal Caco-2 cells via activation of PPARγ and peptidoglycan recognition protein 3. , 2011, The Journal of nutrition.

[56]  K. Moore,et al.  Macrophages in the Pathogenesis of Atherosclerosis , 2011, Cell.

[57]  Brian J. Bennett,et al.  Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease , 2011, Nature.

[58]  J. Dixon,et al.  Bcl-6 and NF-kappaB cistromes mediate opposing regulation of the innate immune response. , 2010, Genes & development.

[59]  B. Stahl,et al.  Prebiotic oligosaccharides: In vitro evidence for gastrointestinal epithelial transfer and immunomodulatory properties , 2010, Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology.

[60]  R. Young,et al.  Histone H3K27ac separates active from poised enhancers and predicts developmental state , 2010, Proceedings of the National Academy of Sciences.

[61]  Egil Lien,et al.  NLRP3 inflammasomes are required for atherogenesis and activated by cholesterol crystals , 2010, Nature.

[62]  Sophie Drouillard,et al.  Efficient synthesis of 6'-sialyllactose, 6,6'-disialyllactose, and 6'-KDO-lactose by metabolically engineered E. coli expressing a multifunctional sialyltransferase from the Photobacterium sp. JT-ISH-224. , 2010, Carbohydrate research.

[63]  C. Glass,et al.  Simple combinations of lineage-determining transcription factors prime cis-regulatory elements required for macrophage and B cell identities. , 2010, Molecular cell.

[64]  G. Pasterkamp,et al.  Toll like receptor 4 in atherosclerosis and plaque destabilization. , 2010, Atherosclerosis.

[65]  K. Moore,et al.  CD36 ligands promote sterile inflammation through assembly of a Toll-like receptor 4 and 6 heterodimer , 2009, Nature Immunology.

[66]  Soo-Ho Choi,et al.  Toll-like receptor-4 and lipoprotein accumulation in macrophages. , 2009, Trends in cardiovascular medicine.

[67]  R. Rieben,et al.  TLR2 and TLR4 agonists induce production of the vasoactive peptide endothelin-1 by human dendritic cells. , 2009, Molecular immunology.

[68]  V. Corces,et al.  CTCF: Master Weaver of the Genome , 2009, Cell.

[69]  D. Ramji,et al.  Interferon gamma: a master regulator of atherosclerosis. , 2009, Cytokine & growth factor reviews.

[70]  P. Shah,et al.  Inflammation and Plaque Vulnerability , 2009, Cardiovascular Drugs and Therapy.

[71]  J. Edwards,et al.  Exploring the full spectrum of macrophage activation , 2008, Nature Reviews Immunology.

[72]  T. Kooistra,et al.  Cytokines and atherosclerosis: a comprehensive review of studies in mice , 2008, Cardiovascular research.

[73]  Joseph L. Goldstein,et al.  Protein Sensors for Membrane Sterols , 2006, Cell.

[74]  P. Tobias,et al.  Modulation of atherosclerosis in mice by Toll-like receptor 2. , 2005, The Journal of clinical investigation.

[75]  A. Brittingham,et al.  Murine Macrophages Produce Endothelin-1 After Microbial Stimulation , 2005, Experimental biology and medicine.

[76]  F. Mach,et al.  Interleukin-1 plays a major role in vascular inflammation and atherosclerosis in male apolipoprotein E-knockout mice. , 2005, Cardiovascular research.

[77]  M. Seishima,et al.  Disruption of tumor necrosis factor-alpha gene diminishes the development of atherosclerosis in ApoE-deficient mice. , 2000, Atherosclerosis.

[78]  Lars Bode,et al.  Inhibition of monocyte, lymphocyte, and neutrophil adhesion to endothelial cells by human milk oligosaccharides , 2004, Thrombosis and Haemostasis.

[79]  Nigel Klein,et al.  Human milk oligosaccharides reduce platelet‐neutrophil complex formation leading to a decrease in neutrophil β 2 integrin expression , 2004, Journal of leukocyte biology.

[80]  E. Fisher,et al.  Emigration of monocyte-derived cells from atherosclerotic lesions characterizes regressive, but not progressive, plaques. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[81]  Tom H. Pringle,et al.  The human genome browser at UCSC. , 2002, Genome research.

[82]  Rachel M. Adams,et al.  The cholesterol-regulated StarD4 gene encodes a StAR-related lipid transfer protein with two closely related homologues, StarD5 and StarD6 , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[83]  Joseph L Goldstein,et al.  SREBPs: activators of the complete program of cholesterol and fatty acid synthesis in the liver. , 2002, The Journal of clinical investigation.

[84]  D. Harn,et al.  The Schistosome Oligosaccharide Lacto-N-neotetraose Expands Gr1+ Cells That Secrete Anti-inflammatory Cytokines and Inhibit Proliferation of Naive CD4+ Cells: A Potential Mechanism for Immune Polarization in Helminth Infections , 2001, The Journal of Immunology.

[85]  C. Kunz,et al.  Human milk oligosaccharides are minimally digested in vitro. , 2000, The Journal of nutrition.

[86]  D. Mangelsdorf,et al.  Regulation of absorption and ABC1-mediated efflux of cholesterol by RXR heterodimers. , 2000, Science.

[87]  G. Sawatzki,et al.  Human milk oligosaccharides are resistant to enzymatic hydrolysis in the upper gastrointestinal tract. , 2000, The American journal of clinical nutrition.

[88]  P. Sakkinen,et al.  Interleukin-6 exacerbates early atherosclerosis in mice. , 1999, Arteriosclerosis, thrombosis, and vascular biology.

[89]  C. Kunz,et al.  Secretion of 13C-labelled oligosaccharides into human milk and infant's urine after an oral [13C]galactose load. , 1999, Isotopes in environmental and health studies.

[90]  A. May,et al.  Crystal structure of the N-terminal domain of sialoadhesin in complex with 3' sialyllactose at 1.85 A resolution. , 1998, Molecular cell.

[91]  L. Staudt,et al.  Control of inflammation, cytokine expression, and germinal center formation by BCL-6. , 1997, Science.

[92]  H. Egge,et al.  High-pH anion-exchange chromatography with pulsed amperometric detection and molar response factors of human milk oligosaccharides. , 1996, Journal of chromatography. B, Biomedical applications.

[93]  H. Egge,et al.  Urinary excretion of lactose and oligosaccharides in preterm infants fed human milk or infant formula , 1996, Acta paediatrica.

[94]  A. Takeshita,et al.  Chronic treatment with interleukin-1 beta induces coronary intimal lesions and vasospastic responses in pigs in vivo. The role of platelet-derived growth factor. , 1996, The Journal of clinical investigation.

[95]  R. Ross,et al.  ApoE-deficient mice develop lesions of all phases of atherosclerosis throughout the arterial tree. , 1994, Arteriosclerosis and thrombosis : a journal of vascular biology.